Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q2 2023 Earnings Call Transcript August 8, 2023
Relmada Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-0.84 EPS, expectations were $0.92.
Operator: Greetings, and welcome to Relmada Therapeutics Inc. Second Quarter 2023 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. It’s now my pleasure to introduce your host, Tim McCarthy, LifeSci Advisors. Please, Mr. Tim, go ahead.
Tim...
